OICR fund provides $1.5 million to Flourinov

The Ontario Institute for Cancer Research (OICR) is investing $1.5 million over three years in Toronto-based Flourinov Pharma Inc to further develop a drug to treat multiple myeloma and some forms of non-Hodgkin's lymphoma. The drug — FV162 — is a highly potent, orally-delivered small molecule proteasome inhibitor which displays significant advantages over existing drugs. The funding comes from OICR's Intellectual Property Development and Commercialization Fund and will assist the privately held Flourinov in meeting the preclinical requirements of Health Canada and the US FDA. Current proteasome inhibitor-based treatment is toxic and requires intravenous delivery....